Details of the Drug

General Information of Drug (ID: DMW4M97)

Drug Name

Clevidipine butyrate

Synonyms

Clevidipine; Cleviprex; 167221-71-8; Clevelox; rac-Clevidipine; H 324/38; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Cleviprex (TN); 3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; METHYL 5-{[(BUTANOYLOXY)METHOXY]CARBONYL}-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]

Affected Organisms

Humans and other mammals

ATC Code

C08CA16: Clevidipine butyrate

C08CA: Dihydropyridine derivatives

C08C: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS

C08: CALCIUM CHANNEL BLOCKERS

C: CARDIOVASCULAR SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

456.3

Logarithm of the Partition Coefficient (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 142 mL/min/kg [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 1 minutes [2]
Metabolism: The drug is metabolized via the esterases in arterial blood []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.6528 micromolar/kg/day [3]
Unbound Fraction: The unbound fraction of drug in plasma is 0.0038% [2]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.58 L/kg [2]

Chemical Identifiers

Formula: C21H23Cl2NO6
IUPAC Name: 5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES: CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
InChI: InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
InChIKey: KPBZROQVTHLCDU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 153994
ChEBI ID: CHEMBL1237132
CAS Number: 167221-71-8
UNII: 19O2GP3B7Q
DrugBank ID: DB04920
TTD ID: D09ELP
INTEDE ID: DR0339
ACDINA ID: D00953

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Modulator	[1]
Voltage-gated L-type calcium channel (L-CaC)	TTXHYV6	NOUNIPROTAC	Inhibitor	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[6]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[6]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Clevidipine butyrate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Clevidipine butyrate and Cariprazine.	Bipolar disorder [6A60]	[7]
Pasireotide	DMHM7JS	Moderate	Increased risk of bradycardia by the combination of Clevidipine butyrate and Pasireotide.	Cushing syndrome [5A70]	[8]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Clevidipine butyrate and OPC-34712.	Depression [6A70-6A7Z]	[7]
Levobetaxolol	DMSREPX	Moderate	Increased risk of cardiac depression by the combination of Clevidipine butyrate and Levobetaxolol.	Glaucoma [9C61]	[9]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Clevidipine butyrate and ITI-007.	Insomnia [7A00-7A0Z]	[7]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Clevidipine butyrate and Siponimod.	Multiple sclerosis [8A40]	[10]
Fingolimod	DM5JVAN	Moderate	Increased risk of atrioventricular block by the combination of Clevidipine butyrate and Fingolimod.	Multiple sclerosis [8A40]	[11]
Ozanimod	DMT6AM2	Moderate	Increased risk of bradycardia by the combination of Clevidipine butyrate and Ozanimod.	Multiple sclerosis [8A40]	[12]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Clevidipine butyrate and Safinamide.	Parkinsonism [8A00]	[13]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Clevidipine butyrate and Iloperidone.	Schizophrenia [6A20]	[7]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Clevidipine butyrate and Amisulpride.	Schizophrenia [6A20]	[7]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Clevidipine butyrate and Asenapine.	Schizophrenia [6A20]	[7]


⏷ Show the Full List of 12 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Oleic acid	E00421	445639	Emulsifying agent; Penetration agent; Solubilizing agent
Edetate disodium	E00186	8759	Complexing agent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Egg phospholipids	E00719	52922414	Surfactant; Dispersing agent; Emulsifying agent; Emulsion stabilizing agent; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Glyceryl monolinoleate	E00639	Not Available	Other agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Clevidipine 25mg/50ml Emulsion	25mg/50ml	Emulsion	Intravenous
Clevidipine 50mg/100ml Emulsion	50mg/100ml	Emulsion	Intravenous
Clevidipine 125mg/250ml Emulsion	125mg/250ml	Emulsion	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
5	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
6	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
7	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
8	Canadian Pharmacists Association.
9	Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
10	Cerner Multum, Inc. "Australian Product Information.".
11	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
12	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
13	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]